DAL enters the post-earnings week with a familiar tension: analysts chasing the stock higher while the market pulls it lower, leaving a widening gap between where the Street thinks Delta belongs and where it is actually trading.
The earnings reaction set the tone. Delta reported Q2 results on July 10 and fell 3.2% the following day — a clean "sell the news" response after a strong run into the print. The stock has lost another 3.5% this week to close at $85.51, reversing a chunk of the 2.9% monthly gain and leaving it roughly 23% below the consensus price target of $105.52. That is not a small gap. The post-earnings dip has widened the discount to the Street just as analysts are finishing their upward revisions, creating the central tension for DAL this week.
The analyst response to Q2 has been unanimously bullish, and the target moves are material. Morgan Stanley raised to $125 from $115, maintaining Overweight — a level that implies nearly 46% upside from Tuesday's close. JP Morgan's Jamie Baker pushed the target all the way to $114 from $85, an unusually large move for a bulge-bracket desk. TD Cowen lifted to $112, UBS to $112, and Citigroup to $110 — all within the past two sessions. The EPS surprise factor ranks in the 89th percentile, and the analyst recommendation differential scores in the 91st, confirming how uniformly constructive the consensus remains. The forward P/E at 13.4x and EV/EBITDA at 8.4x have both expanded over the past month but still look undemanding relative to the earnings trajectory the Street is modeling.
Short interest tells a more complicated story. Bears have been rebuilding positions aggressively since the earnings print. SI jumped 24.6% over the past week to 4.3% of the free float — a meaningful acceleration from around 22.5 million shares at the start of July to 28.1 million now. That is the sharpest seven-day build in the 30-day window. The lending market, however, offers no amplification for squeeze pressure: availability is running at over 1,000% of outstanding short interest, with roughly 384 million shares available to borrow against only 28 million currently borrowed. Cost to borrow is a negligible 0.47%. Short sellers face essentially zero friction in adding exposure. The ORTEX short score has drifted up to 40.4 from 37.2 a fortnight ago — rising, but still well below any threshold that would flag crowded positioning. The setup is bears adding into the gap, not a squeeze dynamic.
Options lean cautiously defensive but not alarmingly so. The put/call ratio is 1.14, modestly above its 20-day average of 1.12 and less than one standard deviation elevated. The 52-week range for the PCR runs from 0.63 to 1.23, putting the current reading in the upper half but nowhere near the annual extreme. Options traders appear mildly protective rather than aggressively positioned for a move either way.
The peer context is worth noting. AAL shed 8.9% on the week and UAL fell 6.2%, making DAL's 3.5% decline look relatively contained. ULCC dropped 13.1%. The sector is under pressure broadly, which partly explains why DAL's post-earnings dip has not been met with more aggressive buying even as analysts raise targets.
The next question for DAL is straightforward: whether the sector-wide selling pressure abates enough for the stock to begin closing the gap to a Street consensus that is now, after this week's revisions, pointing firmly toward $105 and above.
See the live data behind this article on ORTEX.
Open DAL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
